Exploration oxidative stress underlying gastroesophageal reflux disease and therapeutic targets identification: a multi-omics Mendelian randomization study

被引:0
|
作者
Shi, Jiaxin [1 ]
Peng, Bo [1 ]
Xu, Ran [1 ]
Chang, Xiaoyan [1 ]
Wang, Chenghao [1 ]
Zhou, Xiang [1 ]
Zhang, Linyou [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Thorac Surg, 246 Xuefu Rd, Harbin 150081, Peoples R China
关键词
gastroesophageal reflux disease; mQTL; eQTL; pQTL; Mendelian randomization; oxidative stress; SULFITE OXIDASE; PROGNOSTIC BIOMARKER; POLYMORPHISM; CANCER; RISK; GWAS; SUOX; EQTL;
D O I
10.1093/postmj/qgae182
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Gastroesophageal reflux disease (GERD) is a chronic inflammatory gastrointestinal disease, which has no thoroughly effective or safe treatment. Elevated oxidative stress is a common consequence of chronic inflammatory conditions.Methods We employed Summary-data based MR (SMR) analysis to assess the associations between gene molecular characteristics and GERD. Exposure data were the summary-level data on the levels of DNA methylation, gene expression, and protein expression, which obtained from related methylation, expression, and protein quantitative trait loci investigations (mQTL, eQTL, and pQTL). Outcome data, Genome-wide association study (GWAS) summary statistics of GERD, were extracted from the Ong's study (discovery), the D & ouml;nerta & scedil;'s study (replication), and the FinnGen study (replication). Colocalization analysis was performed to determine if the detected signal pairs shared a causative genetic mutation. Oxidative stress related genes and druggable genes were imported to explore oxidative stress mechanism underlying GERD and therapeutic targets of GERD. The Drugbank database was utilized to conduct druggability evaluation.Results After multi-omics SMR analysis and colocalization analysis, we identified seven key genes for GERD, which were SUOX and SERPING1, DUSP13, SULT1A1, LMOD1, UBE2L6, and PSCA. SUOX was screened out to be the mediator, which suggest that GERD is related to oxidative stress. SERPING1, SULT1A1, and PSCA were selected to be the druggable genes.Conclusions These findings offered strong support for the identification of GERD treatment targets in the future as well as for the study of the oxidative stress mechanism underlying GERD. Key Messages What is already known on this topic? - Worries about secondary hypergastrinemia and other side effects linked to long-term PPI usage for gastroesophageal reflux disease (GERD) remain, and ongoing therapy is often necessary. Elevated oxidative stress is a common consequence of many chronic inflammatory conditions. No Mendelian randomization (MR) study has explored the possible causative connection between multi-omics integration data and GERD risk. What this study adds? - The present MR research investigated the possible causal correlations between DNA methylation, gene expression, and protein expression with GERD. We identified a few prospective GERD therapeutic targets and explored the oxidative stress mechanism of GERD. How this study might affect research, practice, or policy? - These results offered strong support for the identification of GERD treatment targets in the future as well as for the study of the oxidative stress mechanism underlying GERD.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Identifying prioritization of therapeutic targets for ankylosing spondylitis: a multi-omics Mendelian randomization study
    Dai, Lingyu
    Xia, Lan
    Su, Guannan
    Gao, Yu
    Jiang, Qingyan
    Yang, Peizeng
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [2] Drug targets for lung cancer: A multi-omics Mendelian randomization study
    Huang, Nan
    Hu, Chao
    Liu, Zheng
    ASIAN JOURNAL OF SURGERY, 2025, 48 (01) : 554 - 555
  • [3] Prioritization of drug targets for thyroid cancer: a multi-omics Mendelian randomization study
    Sun, Hong
    Li, Ling
    Yan, Jingchao
    Huang, Taomin
    ENDOCRINE, 2024, 86 (02) : 732 - 743
  • [4] A multi-omics Mendelian randomization study identifies new therapeutic targets for alcohol use disorder and problem drinking
    Rosoff, Daniel B.
    Wagner, Josephin
    Bell, Andrew S.
    Mavromatis, Lucas A.
    Jung, Jeesun
    Lohoff, Falk W.
    NATURE HUMAN BEHAVIOUR, 2025, 9 (01): : 188 - 207
  • [5] Multi-omics combined to investigate potential druggable therapeutic targets for stroke: A systematic Mendelian randomization study and transcriptome verification
    Shi, Yiming
    Bao, Le
    Li, Yanling
    Ou, Dian
    Li, Jiating
    Liu, Xiaodan
    Deng, Nujiao
    Deng, Changqing
    Huang, Xiaoping
    Zhang, Wei
    Ding, Huang
    JOURNAL OF AFFECTIVE DISORDERS, 2024, 366 : 196 - 209
  • [6] Identification of drug targets for Sjögren's syndrome: multi-omics Mendelian randomization and colocalization analyses
    Bai, Yingjie
    Wang, Jiayi
    Feng, Xuefeng
    Xie, Le
    Qin, Shengao
    Ma, Guowu
    Zhang, Fan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [7] Integrative multi-omics summary-based mendelian randomization identifies key oxidative stress-related genes as therapeutic targets for atrial fibrillation and flutter
    Chen, Shijian
    Sun, Junlong
    Wen, Wen
    Chen, Zhenfeng
    Yu, Ziheng
    FRONTIERS IN GENETICS, 2024, 15
  • [8] Mendelian randomization study of gastroesophageal reflux disease and major depression
    Zheng, Xiaofei
    Zhou, Xin
    Tong, Li
    Gu, Wang
    Wang, Siyu
    Yuang, Wenkang
    Zhang, Chong
    Zhang, Chaoyang
    Zhang, Chao
    Wan, Bangbei
    PLOS ONE, 2023, 18 (09):
  • [9] Gastroesophageal Reflux Disease and Rhinosinusitis: A Bidirectional Mendelian Randomization Study
    Chen, Teng-yu
    Lv, Ming-hui
    Lai, Ren-jie
    Hu, Yu-qi
    Ye, Zhong-kang
    Lv, Qi-liang
    Chen, Bao-yi
    Wu, Jun-tao
    Hong, Haiyu
    Li, Shuo
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2024, 185 (02) : 182 - 189
  • [10] Gastroesophageal reflux disease and osteoporosis: A bidirectional Mendelian randomization study
    Yang, Qinghua
    Huang, Longao
    Xu, Hongyuan
    Feng, Junfei
    Liu, Dun
    Wei, Shengwang
    Jiang, Hua
    MEDICINE, 2025, 104 (14)